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Introduction
A variety of lipids and lipoproteins are involved in the development of vascular pathologies [1] [2] [3] [4] [5] [6] [7] [8] . The role of lipoprotein(a) (Lp(a)) on health and disease has long been of interest 9 . Lp(a) is a unique and still enigmatic lipoprotein particle, composed by a covalent association mediated by a single disulphide bridge between apolipoprotein B 100 (ApoB 100 ; the main protein moiety of lowdensity lipoprotein (LDL)) and apolipoprotein(a) (apo(a), a hydrophilic glycoprotein) [10] [11] [12] [13] [14] ( Figure 1 ). Apo(a) has a high degree of structural homology with plasminogen and can hence antagonize both in vivo and in vitro activity of the patter enzyme 15 . Due to its similarity with LDL and the structural homology with plasminogen, Lp(a) plays an atherothrombotic action 13 .
Although the definitive metabolism of Lp (a) remains to be completely defined, biological evidence seemingly attests that apo(a) is secreted by the liver, rapidly associated with apoB 100 in the circulation, whereas its catabolism pathway is then mainly sustained by the liver (via the hepatic scavenger receptor class B type I and LDL receptor), spleen and kidney 13, 16 .
Intriguingly, a large part of the circulating Lp(a) level is heritable, with its genetic components located in the LPA gene responsible for the encoding of apo(a) [17] [18] [19] [20] [21] [22] . However, Lp (a) concentrations are also dependent on the rate of hepatic apo (a) and apoB 100 secretion 23 . A recent study showed that free apo(a) has a plasma residence time of approximately 11 days compared to only 4 days when the protein is bound to apoB 100 within the Lp(a) particle, thus supporting the concept of an individual metabolism for these components 24 .
Studies of Lp(a) have led to the increasing recognition of its role as a risk biomarker causally associated with vascular pathologies 10, 25 . However, circulating Lp(a) concentrations above 50 mg/dL but less than 200 mg/dL are found in <1% of the general population 11 . A greater understanding of the pathophysiological roles of Lp(a) may lead to clinical measurements of Lp (a) as part of risk prediction and management of cardiovascular disease (CVD). However, 4 the heritable nature of Lp(a) concentrations would raise questions about who should be screened
for and at what age. Lp(a) is modulated by several drugs and presents an interesting therapeutic target 26 . In this review, we aim to summarize and share current knowledge regarding the relationship between Lp(a) and vascular diseases, and to describe other interesting features of this intriguing lipoprotein particle. To date, there have been numerous review papers on the implications of Lp(a) for vascular medicine. We based the present paper on the meta-analyses, which were conducted on this topic, thus ensuring that our discussion reflects the highest quality available evidence.
Lp(a) and cardio-and cerebrovascular disease: an updated summary of evidence
A search of PubMed/Medline was performed to discover all the papers written in an English-language and published before January 15, 2016. The title terms 'lipoprotein (a)' or 'Lp (a)' and 'meta-analysis' or 'meta analysis' or 'metaanalysis' or 'systematic review' or 'study' or 'trial' were used. From the results, we selected high-quality and relevant meta-analyses for inclusion and discussion in this review. We supplemented these with other high-quality papers to expand the scope our work to other aspects of Lp(a) in health and disease.
The relationship between Lp(a) and CVD outcomes has been confirmed by at least three meta-analyses [27] [28] [29] (Table 1 ). An earlier meta-analysis (published in 1998) also suggested that Lp(a) is a risk marker for CVD 30 . The statistical methods of the meta-analysis were identical with those used in more recent studies; accordingly, this paper was not included here. Although all the three papers used prospective studies in the meta-analysis [27] [28] [29] , this presented some difficulties as the outcomes of trials could not be divided into fatal and nonfatal events, or the study populations could not be divided into primary and secondary prevention groups. One meta- 29 . More recently, a review paper summarizing population-based studies has also described a continuous positive association between Lp(a) and the risk of CVD events 31 . Thus, a prognostic value of elevated Lp(a) on CHD events has been repeatedly confirmed, although the magnitude of the effect appears to be globally modest.
The predictive value of Lp(a) on CHD events in a population with a previous history of coronary disease shows great variability between the first study (RR of a population with previous coronary disease, 1.30 , that is lower compared to that of an entire population) 27 and the recent study (RR of a population with previous coronary disease, 2.37, which is higher compared to that of an entire population) 29 . Further work is needed to resolve this discrepancy.
Additionally, a review paper pointed out that in the presence of a high level of LDL, the association between Lp(a) and risk of CVD events was enhanced 31 . This also warrants further investigation.
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The relationship between Lp(a) concentrations and cerebrovascular outcomes has been determined in at least three meta-analyses 28, 29, 32 28 . On the other hand, another study reported no apparent prognostic value of Lp(a) on stroke (RR, 1.10 and 95% CI, 0.97 to 1.25; p=0.14) 29 . Thus, a prognostic value of Lp(a) on cerebrovascular (stroke) events is suggestively confirmed, but still inconsistent ( Table   1) .
Importantly, the magnitude of the prognostic value of Lp(a) on stroke events appeared to be low compared to that of Lp(a) on CVD events. This might be at least in part attributable to the more complicated pathogenetic mechanisms related to the development of stroke compared to those involved in CHD. Similar differences have been also observed by comparing the effect of blood pressure lowering 33 as well as the effect of LDL-cholesterol reduction (especially in secondary prevention patients) 34 on stroke versus the other CVD outcomes. Therefore, the effect of Lp(a) on stroke events 35, 36 is still hard to establish. On the other hand, in a more recent metaanalysis, including 20 trials and totaling 90,904 subjects and 5029 stroke events, an increased Lp(a) concentration has been reported to be an independent risk factor for ischemic stroke (OR, prospective studies), mainly pertinent for young patients (≤55 years of age) who suffered from stroke 37 .
It was also hypothesized that the predictive role of Lp(a) on CVD and stroke events might be associated with inflammation. The role of inflammation or normal food intake in predicting CHD was assessed in 34,829 Danish participants included in the Copenhagen City Heart Study and the Copenhagen General Population Study 38 . This study showed that increased levels of C-reactive protein (CRP) were minimally associated with increased Lp(a) concentrations, and the Lp(a)
value was not significantly modified by normal food intake 38 . A multidirectional Mendelian randomization approach including 100,578 Danish individuals then proved no association between plasma Lp(a) concentrations and low-grade inflammation, despite the causal association with increased risk of myocardial infarction and aortic valve stenosis 39 .
Evidence is being accumulated in terms of the role of Lp(a) on CVD risk. All above issues would deserve further investigation to finally establish the prognostic value of Lp(a) on cardioand cerebro-vascular outcomes.
Lp(a) and cardiometabolic and vascular disease: a unique insight
In recent years, additional meta-analyses and systematic reviews focused on the clinical significance of Lp(a) for vascular diseases have been published (Table 2) . First, a meta-analysis which included population-based observational studies has examined the relationship between apo(a) and cardio-and cerebrovascular disease risk 40 . Apo(a) is a heritable modulator of Lp (a) effects and smaller apo(a) isoforms have been convincingly shown to be associated with higher Lp(a) levels 15, [17] [18] [19] [20] [21] [22] . A significant association between smaller apo(a) isoforms and CHD events compared with larger apo(a) isoforms was described by Erqou et al (RR, 2.08; 95% CI, 1.67 to 8 2.58) 40 . A significant association was also appreciated between smaller apo(a) isoforms and ischemic stroke events compared with larger apo(a) isoforms (RR, 2.14; 95% CI, 1.85 to 2.97) 40 .
The impact of apo(a) on CHD events might be related to Lp(a) concentrations. However, few studies included in this meta-analysis adjusted the data for Lp(a) values for exploring the relationship between apo(a) and outcomes 40 .
Two different meta-analyses, involving case-control studies, investigated the role of Lp(a) in non-CVD pathologies 41, 42 . One article explored the relationship between Lp(a) and venous thrombembolism (VTE). It has been reported that a significant association may exist between increased Lp(a) levels (i.e., >30 mg/dL) and VTE (OR, 1.87; 95% CI, 1.51 to 2.30) 41 . The influence of Lp(a) on arterial pathologies is well-documented, but this article described new insights into the role of Lp(a) in venous pathologies. Another meta-analysis investigated the relationship between CVD risk based on Lp(a) levels and polycystic ovary syndrome (PCOS) 42 .
It was reported that women with PCOS had significantly higher Lp(a) levels than controls (standardized mean difference, 0.81; 95% CI, 0.58 to 1.04) 42 . Notably, it is hence reasonable to put forward an hypothesis that the cardiometabolic propensity in PCOS may be partly caused by Lp(a).
Here, we would add the finding from a recent study (although it was not the meta-analysis and systematic review), the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS), has also shown that there is a causal association between increased Lp(a) concentrations, corresponding LPA risk genotypes, and increased risk of heart failure 43 .
The association was partially mediated by myocardial infarction and aortic valve stenosis 43 .
Finally, a systematic review comprising 6 observational studies, described the relationship between Lp(a) and familiar hypercholesterolemia (FH) in children 9 between Lp(a) and FH in children was noticed 44 . The levels of Lp(a) were found to be higher in FH children, but this association remains controversial 45, 46 . The management of FH in childhood is commonplace to prevent adverse cardiovascular effects 47, 48 . To date, the levels of Lp(a) have been poorly described in FH children, since only a few studies comprising a small number of patients have addressed this association. Therefore, the need of further studies has been proposed although the data were negative 47 ( Table 2 ).
Update on therapies for modulating Lp(a)
Apheresis is the most effective technique to reduce circulating Lp(a) concentrations up to 75% from the baseline levels 49 . Lp(a) is quite refractory to both drug intervention and lifestyle 49, 50 67 .
There have been also data concerning the role of hormonal drugs on Lp(a) reduction. A recent meta-analysis of 12 RCTs with 1009 participants revealed that tibolone, a synthetic steroid with estrogenic, progestogenic, and weak androgenic actions, was found to be effective to decrease plasma Lp(a) concentrations by over 25% in postmenopausal women 68 . A modest reduction of Lp(a) concentrations has been also observed with aspirin treatment 69 . Cholesteryl ester transfer protein (CETP) inhibitors also decrease plasma LDL-cholesterol and Lp (a) concentrations, but the recent disappointment generated by evacetrapib (October 2015) raised significant doubts over the efficacy of drugs in treating increased plasma Lp(a) concentrations 70 . However, the Defining the Safety of Anacetrapib in Patients at High Risk for Coronary Heart Disease (DEFINE) study showed an essential reduction of Lp(a) by 36.4% after 24-weeks of treatment on 2757 patients recruited from 20 countries using anacetrapib 71 .
A dose-dependent reduction of Lp(a) up to 78% was also shown through therapy with a modified antisense oligonucleotide drug 72 84 . However, these results should be interpreted with caution since oral L-carnitine metabolization generates trimethylamine-N-oxide (TMAO), a product strongly involved in increasing CVD risk and accelerating atherosclerosis 85, 86 . Adding dietary allicin from fresh garlic might be a solution to successfully inhibit the pathway of gut microbiota-dependent TMAO production 87 . On the contrary, another meta-analysis on 6 randomized controlled trials and 151 participants did not show a significant effect of garlic on Lp(a) concentrations (mean reduction, 16.86%; p=0.12), despite the inverse association noticed between the changes in plasma concentrations of Lp (a) and duration of supplementation -the significant effect was observed for the supplementation duration >12 weeks (-54.59%; p<0.001) 88 .
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The role of Lp(a) as an independent risk factor of CVD events, irrespective of other coexisted risk factors, is critical. The knowledge of physicians, and consequently the frequency of measurements, is very limited (which is related to the lack of clear recommendations) 5 . The measurement of Lp(a) also remains problematic [89] [90] [91] [92] , and its heterogeneity leads to difficulties when comparing the endpoints of the different studies 91 . At present, immunoassays are generally available to measure Lp(a) levels, but when the antibodies for Lp(a) detection recognize the multiply repeated kringle IV-type 2 domain present in the apo(a) moiey, the apo(a) size can strongly impact assay results. Indeed, the composition of Lp(a), which contains apo(a), apoB 100 and various lipids, is probably the main source of inter-assay viability. Therefore, the levels of Lp(a)-cholesterol, although not commonly assessed in clinical trials, should be seen as a more suitable approach for standardizing (or harmonizing) Lp(a) measurement [89] [90] [91] [92] . One proposed solution was that Lp(a) should be expressed in nmol/L of protein, based on the relationship between the total number of Lp(a) particles and apoB 94 . New methods for Lp(a) measurement are currently in development 91, 94 .
Consideration of the genetics of Lp(a) is important when using this measurement for CVD risk assessment. Recent studies have suggested that the common variants rs1045587 or rs3798220 at LPA locus are significantly associated with increased Lp(a) levels and increased CVD risk 20, 22 . The genetic studies might provide further evidence of the role of Lp (a) in the development of cardio-and cerebro-vascular disease. Since genetic determinants are unaffected by environmental factors, the LPA genotype-scoring system might be useful to establish a personalized treatment 20, 22 . Future studies should address these aspects in various ethnic and/or diseased populations.
The oxidative modification of lipoproteins may be important in the pathophysiology of atherosclerosis 97, 98 . Being a unique lipoprotrein subclass, Lp(a) is relatively easily oxidized.
Various phenomena of Lp(a) oxidation and/or oxidative molecules capable of binding to Lp (a) have been observed in vessel walls 99, 100 . Therefore, oxidized-Lp(a) levels might be more suitable markers for the development of cardio-and cerebro-vascular disease. An assay for oxidized-Lp(a) using the sandwich-ELISA method has been recently developed, thus generating an increased interest in oxidized-Lp(a) determination in CVD research [100] [101] [102] [103] . The monoclonal antibody obtained using oxidizing agents in this assay was shown to react only with oxidized Lp(a), but not with native Lp(a) and LDL 100. The antibody detected a specific epitope that appears when the Lp(a) particle has been exposed to oxidative stress 100 . Although Lp(a) is easily oxidized, oxidized-Lp(a) is not well correlated to native Lp(a) level in our experience. Even in low oxidative Lp(a) environment, the mobility of oxidized-Lp(a) is changed, being different from that of native Lp(a) in agarose gel electrophoresis analysis 100 . Additional assays for Lp (a) oxidation are needed 101 , as are more studies to address the implication of Lp (a) Some questions remain in relation to the controversial anti-tumor function of Lp(a) 110 . In experimental studies a reduction of tumor cells growth by apo(a) was demonstrated 111, 112 . The degradation of apo(a) inside of Lp(a), produces various size of kringles and this process was associated with anti-angiogenesis and anti-tumor properties 110 . In addition, although the biological mechanisms remain unclear, high Lp(a) levels were repeatedly detected in the very elderly, suggesting that elevated Lp(a) might be linked with longevity 113 . The putative anticancer properties of Lp(a) and its metabolites may at least in part explain the association with longevity, but additional studies are warranted to define the potential beneficial effects exerted by Lp(a) at physiological concentrations. Some studies reported that high Lp(a) levels are predictive markers of CVD outcomes and including mortality, while others reported no apparent relationship between Lp(a) and nonvascular or all-cause mortality (Table 1 ) 28, 29 . It is still unknown if these results are related to the influence of Lp(a) on cancer or longevity. A recent prospective study reported that high levels of Lp(a) are beneficial for cancer-and all-cause mortality 114 . These findings may be increasingly important in the future when CVD events are more susceptible to treatment and the long life-expectancy results in an aging population.
Conclusions
The present paper outlines the current state of knowledge and evidence regarding the effects of Lp(a) on CVD risk by summarizing the results of the available data from meta-analyses and systematic reviews. The literature supports the predictive value of Lp(a) on CVD outcomes, although the effect size is modest. Lp(a) would also appear to have an effect on cerebrovascular (stroke) outcomes, although the effect appears to be smaller than that for CVD outcomes.
Consideration of apo(a) isoforms and LPA genetics, in relation to circulating Lp (a) concentrations, may enhance improving the clinical practice in vascular medicine. We describe recent advances in Lp(a) research and highlight areas where further study is needed, including the measurement of Lp(a) and its involvement in additional pathophysiological processes. 
